INTRODUCTION
The Mycobacterium tuberculosis genome encodes over 90 confirmed and predicted lipoproteins as both cell wall-bound and secreted molecules, with functions in cell adhesion and invasion, signaling and transmembrane transport. 1 Acylation of lipoproteins is facilitated by the lipobox that serves as a recognition site for enzymes involved in the lipoprotein biosynthesis pathway. The lipobox consists of three amino acids followed by a universally conserved cysteine residue to which fatty acids are covalently attached. 2 Fatty acids (collectively referred to here as acyl chains) contained within mycobacterial lipoproteins include, but are likely not limited to, palmitic, oleic, and tuberculostearic acid. 3 two ester-bound acyl residues attached to the conserved N-terminal cysteine residue forming a diacylglyceryl moiety, and an additional amide-bound acyl chain attached to the amino group. 2 Multiple Toll-like receptors (TLR) have roles in the host recognition of M. tuberculosis, including TLR2, 4-6 TLR4, 7 TLR8, 8, 9 and TLR9. [10] [11] [12] M. tuberculosis lipoproteins such as the 19 kDa lipoprotein are wellknown TLR2 agonists. 13 TLR2 recognizes lipoproteins in conjunction with TLR1 14 and TLR6, 15 which initiates conserved intracellular signaling events that result in the activation of a conserved host defense program, including the expression of inflammatory cytokines. 16 Synthetic lipopeptides have been instrumental in defining the current paradigm of coreceptor involvement in the TLR2-mediated recognition of lipoproteins. 13, 17 Triacylated lipopeptides such as Pam 3 CSK 4 are recognized by TLR2 in conjunction with TLR1, 13 whereas diacylated lipopeptides such as Pam 2 CSK 4 are recognized in conjunction with TLR6. 17 Aside from an extensive number of functional studies, this paradigm is supported by X-ray crystallography studies confirming the TLR2/TLR1 complex with cocrystallized Pam 3 CSK 4 , 14 as well as the TLR2/TLR6 complex with cocrystallized Pam 2 CSK 4 . 15 However, systematic manipulation of the structural properties of synthetic lipopeptides has demonstrated that some lipopeptides elicit cellular responses outside of the TLR1/TLR6 tri-/diacylation paradigm. 18 This highlights the limitations of the current model in accommodating the complexity of naturally occurring ligands. RP105 (CD180) is a TLR family member expressed by B cells, macrophages, and dendritic cells. 19 It is most closely related to TLR4 in terms of structure of its extracellular domain. 20 Surface expression and functions of RP105 rely on association with MD-1, 21 a homolog of the TLR4 accessory molecule, MD-2. 22 However, RP105 is distinct from other TLRs in its lack of the conserved intracellular Toll-interleukin-1 receptor (TIR) domain, which is required for initiation of canonical TLR signaling. 23, 24 Thus, RP105 has been proposed to require a signalingcompetent partner to contribute to host cell activation. In myeloid cells, RP105 physically and functionally interacts with both TLR4 and TLR2. 20, 25 We previously identified RP105 as a positive regulator of proinflammatory cytokine responses in M. tuberculosis-and M. bovis bacille Calmette Guerin (BCG)-infected macrophages. 25, 26 Mice deficient in RP105 displayed elevated bacterial burden and pathology in the chronic phase of M. tuberculosis infection. 25 M. tuberculosis ΔlspA mutant bacteria lack mature lipoproteins and did not induce an RP105-dependent response in macrophages. This indicated that mature mycobacterial lipoproteins are RP105 agonists. Indeed, the M. tuberculosis 19 kDa lipoprotein, a known TLR2/TLR1 agonist, 13 activated macrophages in an RP105-dependent manner. 25 Functional and physical interactions of RP105 with TLR2 in the context of mycobacterial infection 25 suggest that RP105 may function as a coreceptor for TLR2.
However, how RP105 contributes to recognition of bacterial lipoproteins is currently unknown. To address this, we set out to characterize lipopeptide properties that confer RP105 agonism.
MATERIALS AND METHODS

Reagents
The synthesis of peptides and lipopeptides was carried out by fully automated solid-phase peptide synthesis and Fmoc/tBu chemistry on chlorotrityl resins. To generate lipopeptides, the peptide resin was elongated with the unusual amino acid Fmoc-S-(2,3-dihydroxy-2(RS)-propyl)-cysteine (Fmoc-Cys(Dhc)) 27 followed by esterification on solid phase with palmitic acid. After Fmoc-de-protection, the lipopeptides were either cleaved from the resins and side chain deprotected or fur- 
Mice
Rp105 −/−25 and Tlr1 −/−13 mice have been described previously. 
Primary macrophage culture
Macrophage stimulation assays
Unless stated otherwise, synthetic M. tuberculosis 19 kDa lipoproteinbased lipopeptides were used at 500 nM and Pam 3 CSK 4 was used at 10 ng/ml. LPS was used at 100 EU/ml. Purified M. tuberculosis 19 kDa lipoprotein was used at 1 g/ml. Antibodies were added 1 h prior to cell stimulation. Cytokine concentrations in cell culture supernatants were measured using ELISA (TNF DuoSet, R&D Systems; IL-6 OptEIA, BD Biosciences).
Statistical analyses
Comparisons of two groups were conducted using two-tailed paired Student's t test; 95% confidence interval. Comparisons of more than two groups were conducted using one-way ANOVA followed by Dunnett's multiple comparisons test. P values < 0.05 were considered statistically significant. GraphPad Prism 7 was used to create all graphs and perform all statistical analyses. induces RP105-dependent cytokine release by macrophages. 25 To improve solubility, four C-terminal lysine residues were added to this RP105 agonist. an RP105-dependent manner across a dose range (Figure 2A, B) . 
Polar amino acids confer RP105-agonistic properties
As RP105-dependent macrophage activation did not seem to be dominated by the acylation pattern of RP105 agonistic synthetic lipopeptides, we next focused on the contribution of the peptide moiety. 15 To investigate whether specific Nterminal amino acids conferred RP105-agonism to the synthetic lipopeptides, a four-lysine motif was inserted at the N-terminus.
The resulting lipopeptide, Pam 3 CSK 4 -SSNKSTTGSGETTTA (Table 1) retained RP105-agonistic capacity ( Figure 4B ), indicating that RP105-dependent macrophage activation by this RP105 agonist is not determined by the first 6 amino acids of the N-terminus.
We next focused our attention on the polar threonine residues in 
DISCUSSION
Systematic manipulation of RP105-agonistic synthetic lipopeptides revealed that RP105-dependent macrophage activation was preserved in di-and triacylated lipopeptide variants, setting RP105
agonism apart from the paradigm of TLR1-and TLR6-dependent Results are means ± SEM of three independent experiments, each performed in duplicates. The two groups in each experiment were compared using Student's t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0. agonist, 13 in addition to being an RP105 agonist. 25 The RP105-agonistic synthetic lipopeptides used in this study were fully dependent on TLR2 to activate macrophages, whereas RP105 deficiency only partially diminished macrophage cytokine production. This likely reflects additional contributions of TLR2/1 and/or TLR2/6 complexes, and we confirmed TLR1 dependency for the triacylated lipopeptide -induced IL-6 and TNF production. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 15aa = SSNKSTTGSGETTTA variants independent of their RP105-agonistic properties. TLR2 and RP105 coimmunoprecipitate, and colocalize on the macrophage cell surface. 25 It is worth noting that the synthetic RP105 agonistic lipopeptides used in this study contained palmitic acid (C16), whereas the diacylglyceryl residues of the native M. tuberculosis 19 kDa lipoprotein consist of both palmitic acid and tuberculostearic acid (C19). 3 This has genuine biological implications as fatty acid chain length influences the ability of TLR2 to engage with lipopeptide acyl chains. 30 However, our data demonstrate that RP105 agonism is preserved in di-as well as tripalmitoylated lipopeptides, supporting the notion that the nature of the acyl chains is unlikely to determine RP105 agonism.
While RP105 has no known lipid-binding domains, MD-1 possesses a lipid-binding pocket. 37 It has been hypothesized that in a putative TLR2/RP105 complex, the lipid-binding pocket of TLR2 may align with that of MD-1 when two RP105 molecules are arranged in a "headto-head" orientation. 38 
